Shaping The Future of Regulatory Writing Education
Facet Life Sciences is proud to share that Dana Blue, Strategic Program Champion and Medical Writing Team Manager, has been asked to rejoin the Regulatory Writing Subcommittee of the American Medical Writers’ Association (AMWA) Education Committee, which designs and develops comprehensive worldwide training programs.
This marks Dana’s fourth consecutive year volunteering with the AMWA to prepare early- and mid-career writers for the realities of novel drug and device submissions.
- In 2023 and 2024, Dana served on the Annual Conference subcommittee to support the development of broadly applicable Medical Writing courses.
- In 2025, Dana served on the inaugural Regulatory Writing subcommittee, where she helped launch three writing programs focused on beginning and advanced Clinical Study Reports (CSRs) development and Investigator Brochures (IBs) creation.
- In 2026 — beyond deepening the Regulatory Writing offering — AMWA programming will also expand on Artificial Intelligence (AI), Scientific Publications, Specialty Area Writing, and more.
This appointment is a testament to Dana’s deep technical expertise and also reflects Facet’s ongoing commitment to stronger clinical development and faster, first-time approvals. “Because we work with small companies, we have a much more in-depth understanding of our audience — the FDA or other regulatory bodies,” says Dana. “The AMWA helps train writers on a large scale, building a future pool of extremely talented writers.”
Dana sits at the intersection of regulatory affairs and medical writing at Facet and has hands-on experience supporting Food & Drug Administration (FDA) submissions for emerging biotech and pharma. Facet helps small science teams understand how FDA reviewers assess submission documents, their priorities, and the order in which they read them.
Interested in working with a strategic regulatory expert like Dana to determine your path to and through the FDA? Schedule a call with Facet today.
gET sOCIAL